During this period, the NCGC has worked to validate and characterize hits previously identified in the primary screen, and the larger collaborative team is working on demonstrating proof-of-principle in in vivo studies. As a center, the NCGC has fostered and maintained over 110 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to dozens of high-throughput screens and a number of medicinal chemistry campaigns to further improve on screening hits, providing our collaborators and the general research community with publications and a variety of promising small molecule probes and leads. In addition, the NCGC has worked to advance a number of informatic initiatives to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease.
| Hu, Xin; Myhr, Courtney; Huang, Zaohua et al. (2016) Structural Insights into the Activation of Human Relaxin Family Peptide Receptor 1 by Small-Molecule Agonists. Biochemistry 55:1772-83 |
| Huang, Zaohua; Myhr, Courtney; Bathgate, Ross A D et al. (2015) Activation of Relaxin Family Receptor 1 from Different Mammalian Species by Relaxin Peptide and Small-Molecule Agonist ML290. Front Endocrinol (Lausanne) 6:128 |
